The stock of Protagonist Therapeutics Inc (PTGX) has gone down by -13.85% for the week, with a -15.30% drop in the past month and a -4.95% drop in the past quarter. The volatility ratio for the week is 5.93%, and the volatility levels for the past 30 days are 3.91% for PTGX.. The simple moving average for the past 20 days is -13.17% for PTGX’s stock, with a 12.21% simple moving average for the past 200 days.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio of 14.94x that is above its average ratio. Additionally, the 36-month beta value for PTGX is 2.18. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PTGX is 56.31M and currently, short sellers hold a 5.83% ratio of that float. The average trading volume of PTGX on November 15, 2024 was 601.77K shares.
PTGX) stock’s latest price update
Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has dropped by -2.96 in relation to previous closing price of 41.04. Nevertheless, the company has seen a loss of -13.85% in its stock price over the last five trading days. zacks.com reported 2024-11-13 that Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Wedbush repeating the rating for PTGX by listing it as a “Outperform.” The predicted price for PTGX in the upcoming period, according to Wedbush is $58 based on the research report published on November 05, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $65. The rating they have provided for PTGX stocks is “Buy” according to the report published on September 24th, 2024.
Truist gave a rating of “Buy” to PTGX, setting the target price at $60 in the report published on September 09th of the current year.
PTGX Trading at -12.68% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.54% of loss for the given period.
Volatility was left at 3.91%, however, over the last 30 days, the volatility rate increased by 5.93%, as shares sank -14.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.64% lower at present.
During the last 5 trading sessions, PTGX fell by -13.50%, which changed the moving average for the period of 200-days by +40.22% in comparison to the 20-day moving average, which settled at $45.88. In addition, Protagonist Therapeutics Inc saw 73.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Ali Asif, who sale 14,203 shares at the price of $44.49 back on Sep 11 ’24. After this action, Ali Asif now owns 34,960 shares of Protagonist Therapeutics Inc, valued at $631,872 using the latest closing price.
Waddill William D., the Director of Protagonist Therapeutics Inc, sale 8,000 shares at $45.00 during a trade that took place back on Sep 10 ’24, which means that Waddill William D. is holding 12,000 shares at $360,000 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.53. The total capital return value is set at 0.27. Equity return is now at value 40.97, with 36.59 for asset returns.
Currently, EBITDA for the company is -90.34 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 7.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.70.
Conclusion
In conclusion, Protagonist Therapeutics Inc (PTGX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
